Journal of Clinical Oncology
Articles in this Issue
Surgical efficacy of neoadjuvant mono-immunotherapy for T <sub>4</sub> -deficient mismatch repair colon cancer: A prospective, single-arm, phase II trial.
145 Background: Given that Deficient Mismatch Repair (dMMR) colon cancer patients respond poorly to conventional chemother...
A randomized phase II trial of medical cannabis to reduce symptom burden in patients with newly diagnosed advanced pancreatic cancer (CanPan).
697 Background: Patients with advanced pancreatic adenocarcinoma experience severe, persistent symptoms. Medical cannabis...
Efficacy and safety of first-line immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone in advanced cholangiocarcinoma: A meta-analysis.
571 Background: Cholangiocarcinoma (CAA) is increasing. Typically, the majority of patients with CCA are diagnosed at an a...
Quantifying MLH1 promoter methylation via liquid biopsy.
25 Background: MLH1 is one of the primary genes involved in mismatch repair (MMR). Promoter methylation of MLH1 is known t...
The effect of Medicaid expansion on time to treatment and survival in metastatic colorectal cancer: A statewide analysis.
48 Background: Medicaid expansion (ME) has been associated with improvements in colorectal cancer outcomes, largely driven...
Intratumoral immune landscape changes after neoadjuvant chemoradiation in esophageal cancer.
443 Background: Neoadjuvant chemoradiation (nCRT) remains a standard of care in esophageal cancer. Although adjuvant Nivol...
Integrating unsupervised visual representation learning on whole-slide images of bile duct strictures for enhanced diagnostics and prognostics.
481 Background: Biliary obstructive disorders represent a major global health burden. Endoscopic retrograde cholangiopancr...
A single center prospective study to evaluate effectiveness of 68Ga-FAPI PET/CT in the initial evaluation of signet ring cell carcinoma of the stomach.
293 Background: Signet ring cell carcinomas (SRC) is a well know limitation for FDG PET/CT. SRC is rich in cancer associat...
Supporting utility and representation in genomics-based clinical trial enrollment (SURGE): Interim findings.
40 Background: Disparities in clinical trial enrollment are well documented, yet little attention is paid to genomic testi...
BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma.
242 Background: BXQ-350 is a first-in-class biologic nanovesicle of Saposin C, an allosteric activator of sphingolipid met...
Efficacy of combination therapy with anti-EGFR antibody as first-line treatment for <i>RAS</i> wild-type metastatic colorectal cancer according to anatomical tumor location from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
146 Background: The combination of anti-EGFR antibody plus doublet chemotherapy has become the standard first-line treatme...
A real-world study of claudin 18.2 (CLDN18.2) association with molecular subtypes, mutations/biomarkers, immune landscapes, and gene signatures and prognostic value in pancreatic ductal adenocarcinoma (PDAC).
744 Background: CLDN18.2, a validated therapeutic target and biomarker in gastric cancer, is often highly expressed in PDA...
Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
709 Background: Spevatamig (PT886) is an IgG1-based bispecific antibody targeting claudin 18.2 (CLDN18.2) and CD47 with an...
Global practice patterns of radiotherapy utilization in pancreatic adenocarcinoma.
670 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer requiring multi-modality treatment. Radiot...
Final results of a phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC).
395 Background: Second-line treatment options for advanced gastric cancer remain limited. This open-label, single-arm phas...
Genomic predictors and evolutionary correlates of chemotherapy response in pancreatic ductal adenocarcinoma.
767 Background: Pancreatic ductal adenocarcinoma (PDAC) remains lethal. Neoadjuvant therapy (NAT) is increasingly applied...
Phase II trial of systemic therapy plus intraperitoneal (IP) paclitaxel (PTX) in gastric/GEJ cancer peritoneal carcinomatosis (GPC): STOPGAP trial.
359 Background: Peritoneal carcinomatosis (PC) is a common and deadly metastasis in gastric cancer. Systemic therapy alone...
No operation after short-course radiotherapy followed by consolidation chemotherapy in locally advanced rectal cancer (NOAHS-ARC): A prospective, phase II trial.
142 Background: Total neoadjuvant therapy (TNT) improves tumor response in locally advanced rectal cancer (LARC). Watch-an...
A CDC based analysis of anal cancer mortality disparities in US adults aged ≥65 years.
3 Background: Anal cancer rates have climbed markedly in recent decades, with parallel rises in incidence and mortality. W...
Multicenter, nonrandomized clinical trial to evaluate the efficacy and toxicity of a combination of targeted therapy and chemotherapy in the second-line treatment of patients with metastatic inoperable colorectal cancer.
TPS247 Background: BRAF mutation found in 8-10% of colorectal cancers (CRC). BRAF mutation in tumor determines poor progno...
Genomic profiling of epithelial neoplasms of the appendix: Insights across histological subtypes and histological grades.
847 Background: The biological behavior of appendiceal epithelial neoplasms (AENs) depends on histological subtype and gra...
Changing landscape of multidisciplinary management in locally advanced rectal cancer (2015-2023).
57 Background: Multidisciplinary management of locally advanced rectal cancer has evolved over the last decade with public...
Optimising outcomes in young-onset metastatic colorectal cancer from a multidisciplinary model of care.
56 Background: Australia has the highest incidence of young-onset colorectal cancer (yo-CRC) globally (1). Many young pati...
Bold-100-001: A randomized phase 2 study of bold-100 plus FOLFOX vs FOLFOX in patients with refractory metastatic colorectal cancer.
TPS277 Background: Effective treatment for patients with metastatic colorectal cancer (mCRC) who have progressed on first-...
Clinical trials on the menu: A patient- and clinician-validated plain-language platform for pancreatic cancer.
757 Background: Fear and urgency define the journey of pancreatic cancer. Most patients present with advanced disease, whe...